Alginate-encapsulated HepG2 cells in a fluidized bed bioreactor maintain function in human liver failure plasma

Artificial Organs

Volumn 33, Issue 12, 2009, Pages 1117-1126

  Coward, Sam M ^a   Legallais, Cécile ^b   David, Bertrand ^b   Thomas, Michael ^c   Foo, Ying ^d   Mavri Damelin, Demetra ^a   Hodgson, Humphrey J ^a   Selden, Clare ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITÉ DE TECHNOLOGIE DE COMPIÈGNE   (France)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

Artificial liver; Bioreactors; Hepatocytes; Liver failure; Plasma; Tumor cell line

Indexed keywords

ALGINATE; ARTIFICIAL ORGANS; BIOCONVERSION; CELL CULTURE; CELLS; FLUIDIZED BEDS; METABOLISM; MICROGRAVITY; MICROGRAVITY PROCESSING; UREA;

ARTIFICIAL LIVER; BIOARTIFICIAL LIVER; CELLULAR COMPONENTS; FLUIDIZED BED BIOREACTORS; HEP-G2 CELLS; HEPATOCYTES; HUMAN LIVER; LIVER FAILURE; PERFORMANCE; TUMOR CELL LINES;

BIOREACTORS;

ALANINE AMINOTRANSFERASE; ALGINIC ACID; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; GLUCOSE; LACTATE DEHYDROGENASE; LACTIC ACID; UREA;

ADULT; AGED; ARTICLE; BILIRUBIN BINDING; BIOARTIFICIAL LIVER; CASE REPORT; CELL DAMAGE; CELL ENCAPSULATION; CELL STRAIN HEPG2; CELL VIABILITY; CONTROLLED STUDY; DETOXIFICATION; DNA MODIFICATION; ENZYME ACTIVITY; FEMALE; FLUIDIZED BED REACTOR; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LIVER FAILURE; LIVER PERFUSION; MICROGRAVITY; PLASMA; PRIORITY JOURNAL; UREA CYCLE;

EID: 74049129971     PISSN: 0160564X     EISSN: 15251594     Source Type: Journal    
DOI: 10.1111/j.1525-1594.2009.00821.x     Document Type: Article

References (28)

1. Wigg AJ, Padbury RT. Liver support systems: promise and reality. J Gastroenterol Hepatol 2005 20 : 1807 1816.
2. Demetriou AA, Brown RS Jr., Busuttil RW, et al. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg 2004 239 : 660 667.
3. Ellis AJ, Hughes RD, Wendon JA, et al. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology 1996 24 : 1446 1451.
4. Selden C, Hodgson H. Cellular therapies for liver replacement. Transpl Immunol 2004 12 : 273 288.
5. Yamashita Y, Shimada M, Tsujita E, et al. Polyurethane foam/spheroid culture system using human hepatoblastoma cell line (Hep G2) as a possible new hybrid artificial liver. Cell Transplant 2001 10 : 717 722.
6. Coward SM, Selden C, Mantalaris A, Hodgson HJ. Proliferation rates of HepG2 cells encapsulated in alginate are increased in a microgravity environment compared with static cultures. Artif Organs 2005 29 : 152 158.
7. Khalil M, Shariat-Panahi A, Tootle R, et al. Human hepatocyte cell lines proliferating as cohesive spheroid colonies in alginate markedly upregulate both synthetic and detoxificatory liver function. J Hepatol 2001 34 : 68 77.
8. Rahman TM, Selden C, Khalil M, Diakanov I, Hodgson HJ. Alginate-encapsulated human hepatoblastoma cells in an extracorporeal perfusion system improve some systemic parameters of liver failure in a xenogeneic model. Artif Organs 2004 28 : 476 482.
9. Nagaki M, Naito T, Ohnishi H, Akaike T, Muto Y, Moriwaki H. Effects of plasma from patients with fulminant hepatic failure on function of primary rat hepatocytes in three-dimensional culture. Liver Int 2005 25 : 1010 1017.
10. Papadimitriou D, Arkadopoulos N, Kouskouni E, et al. Hepatocyte function during experimental use of a bioartificial liver. Transplant Proc 2004 36 : 1741 1743.
11. Chen Z, Ding Y, Li G. Configuration of a new bioartificial liver support system and in vitro evaluation of its functions. Ann Clin Lab Sci 2005 35 : 7 14.
12. David B, Dufresne M, Nagel MD, Legallais C. In vitro assessment of encapsulated C3A hepatocytes functions in a fluidized bed bioreactor. Biotechnol Prog 2004 20 : 1204 1212.
13. Donato MT, Gomez-Lechon MJ, Castell JV. A microassay for measuring cytochrome P450IA1 and P450IIB1 activities in intact human and rat hepatocytes cultured on 96-well plates. Anal Biochem 1993 213 : 29 33.
14. Mavri-Damelin D, Damelin LH, Eaton S, Rees M, Selden C, Hodgson HJ. Cells for bioartificial liver devices: the human hepatoma-derived cell line C3A produces urea but does not detoxify ammonia. Biotechnol Bioeng 2008 99 : 644 651.
15. Blackard WG, Clore JN, Powers LP. A stimulatory effect of FFA on glycolysis unmasked in cells with impaired oxidative capacity. Am J Physiol 1990 259 (3 Part 1 E451 6.
16. van de Kerkhove MP, Hoekstra R, Chamuleau RA, van Gulik TM. Clinical application of bioartificial liver support systems. Ann Surg 2004 240 : 216 230.
17. Abrahamse SL, van de Kerkhove MP, Sosef MN, Hartman R, Chamuleau RA, van Gulik TM. Treatment of acute liver failure in pigs reduces hepatocyte function in a bioartificial liver support system. Int J Artif Organs 2002 25 : 966 974.
18. Ito Y, Eguchi S, Kamohara Y, et al. Influence of serum from rats with fulminant hepatic failure on hepatocytes in a bioartificial liver system. Int J Artif Organs 2004 27 : 303 310.
19. Mavri-Damelin D, Eaton S, Damelin LH, Rees M, Hodgson HJ, Selden C. Ornithine transcarbamylase and arginase I deficiency are responsible for diminished urea cycle function in the human hepatoblastoma cell line HepG2. Int J Biochem Cell Biol 2007 39 : 555 564.
20. McCloskey P, Tootle R, Selden C, Larsen F, Roberts E, Hodgson HJ. Modulation of hepatocyte function in an immortalized human hepatocyte cell line following exposure to liver-failure plasma. Artif Organs 2002 26 : 340 348.
21. Hughes RD, Yamada H, Gove CD, Williams R. Inhibitors of hepatic DNA synthesis in fulminant hepatic failure. Dig Dis Sci 1991 36 : 816 819.
22. Shi Q, Gaylor JD, Cousins R, Plevris J, Hayes PC, Grant MH. The effects of serum from patients with acute liver failure on the growth and metabolism of Hep G2 cells. Artif Organs 1998 22 : 1023 1030.
23. Yamada H, Toda G, Yoshiba M, et al. Humoral inhibitor of rat hepatocyte DNA synthesis from patients with fulminant liver failure. Hepatology 1994 19 : 1133 1140.
24. Gohda E, Tsubouchi H, Nakayama H, et al. Human hepatocyte growth factor in plasma from patients with fulminant hepatic failure. Exp Cell Res 1986 166 : 139 150.
25. Tsubouchi H, Hirono S, Gohda E, et al. Human hepatocyte growth factor in blood of patients with fulminant hepatic failure. I. Clinical aspects. Dig Dis Sci 1991 36 : 780 784.
26. Catapano G, De Bartolo L, Lombardi CP, Drioli E. The effect of catabolite concentration on the viability and functions of isolated rat hepatocytes. Int J Artif Organs 1996 19 : 245 250. (Pubitemid 26132416)
27. Newsome PN, Tsiaoussis J, Masson S, et al. Serum from patients with fulminant hepatic failure causes hepatocyte detachment and apoptosis by a beta(1)-integrin pathway. Hepatology 2004 40 : 636 645.
28. Richert L, Liguori MJ, Abadie C, et al. Gene expression in human hepatocytes in suspension after isolation is similar to the liver of origin, is not affected by hepatocyte cold storage and cryopreservation, but is strongly changed after hepatocyte plating. Drug Metab Dispos 2006 34 : 870 879.